| Autor: |
Yosuke Takamiya, Chiyori Imanaga, Amane Ike, Akira Kawamura, Hidenori Urata |
| Jazyk: |
angličtina |
| Rok vydání: |
2025 |
| Předmět: |
|
| Zdroj: |
International Journal of Cardiology. Cardiovascular Risk and Prevention, Vol 24, Iss , Pp 200359- (2025) |
| Druh dokumentu: |
article |
| ISSN: |
2772-4875 |
| DOI: |
10.1016/j.ijcrp.2024.200359 |
| Popis: |
Purpose: To examine the efficacy and safety of pemafibrate in outpatients with hypertriglyceridemia, including alcoholic hypertriglyceridemia. Method: This multicenter, open-label, prospective observational study (C20-07-009) included outpatients with hypertriglyceridemia being treated with pemafibrate who were registered at Fukuoka University Chikushi Hospital or associated clinics. Endpoints were changes in serum triglyceride (TG) and high-density lipoprotein cholesterol (HDL-C), hepatic biomarkers, and other blood values from baseline to 24 weeks and safety. Patients were compared according to alcohol drinking. Result: From October 2020 to March 2022, 203 patients were registered at 14 facilities. We analyzed 174 patients (mean age, 65.5 years) with baseline fasting TG values who continued pemafibrate for 24 weeks; 55 % drank alcohol, and 35 % were receiving statins. Median fasting TG was 284 mg/dL (IQR, 228–392 mg/dL) at baseline and decreased significantly to 141 mg/dL (IQR, 108–194 mg/dL) at 24 weeks (p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
